Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen

American Journal of Hematology

Volumn 74, Issue 1, 2003, Pages 46-51

  Shapiro, Michael ^a   Wasik, Mariusz A ^a,c   Junkins Hopkins, Jacqueline M ^a   Rook, Alain H ^a   Vittorio, Carmela C ^a   Itakura, Haruka ^a   Frankel, Matthew C ^a   Georgala, Sofia ^b   Schuster, Stephen J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (United States)

Author keywords

Blastic NK cell lymphoma leukemia; Hyper CVAD

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CASE REPORT; CLINICAL FEATURE; ELDERLY CARE; GENE REARRANGEMENT; HUMAN; LEUKEMIA REMISSION; LYMPH NODE; LYMPHOMA; MALE; NATURAL KILLER CELL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUVA; SKIN; TREATMENT OUTCOME; VISCERA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA, T-CELL; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; VINCRISTINE;

EID: 0042424858     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10381     Document Type: Article

References (33)

1. Loughran TP. Clonal diseases of large granular lymphocytes. Blood 1993:82:1-14.
2. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res 1999;23:615-624.
3. Kantarijian HM, O'Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocyte leukemia. J Clin Oncol 2000;18:547-561.
4. Thomas D, Kantarijian H, O'Brien S, et al. Outcome with the Hyper-CVAD regimen in lymphoblastic lymphoma (LL). Proc Am Soc Clin Oncol 1999;18:11a (Abstr 38).
5. Chan JKC, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997;89:4501-4513.
6. Kawano S, Tatsumi E, Yoneda N, et al. Novel leukemic lymphoma with probable derivation from immature stage of natural killer lineage in an aged patient. Hematol Oncol 1995;13:1.
7. Kobashi Y, Nakamura S, Sasajima YS, et al. Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Histopathology 1996;28:111.
8. Ko YH, Kim SH, Ree HJ. Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wright type pseudorosettes formation. Histopathology 1998;33:547-553.
9. Nagatani T, Okazawa H, Kambara T, et al. Cutaneous monomorphous CD4- and CD56-positive large cell lymphoma. Dermatology 2000; 200:202-208.
10. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995;19:284-296.
11. Bower CPR, Standen GR, Pawade J, Knechtli CJ, Kennedy CTC. Cutaneous presentation of steroid responsive blastoid natural killer cell lymphoma. Br J Dermatol 2000;142;1017-1020.
12. Matano S, Nakamura S, Nakamura S, et al. Monomorphic agranular natural killer cell lymphoma/leukemia with no Epstein-Barr virus association. Acta Haematol 1999;101:206-208.
13. Kameoka J, Ichinohasama R, Tanaka M, et al. A cutaneous agranular CD2- CD4+ CD56+ 'Lymphoma.' Report of two cases and review of the literature. Am J Clin Pathol 1998;110:478-488.
14. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol 1997;21:1223-1230.
15. Feuillard, J, Jacob M-C, Valensi F, et al. Clinical and biologic features of CD4+CD56+ malignancies. Blood 2002;99:1556-1563.
16. Chan JKC, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer Press; 2001. p 214-215.
17. Bayerl MG, Rakozy CK, Mohamed AN, et al. Blastic natural killer cell lymphoma/leukemia. A report of seven cases. Am J Clin Pathol 2002; 117:41-50.
18. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-111.
19. DiGiuseppe JA, Mann RB. Blastic natural killer cell. [Letter]. Am J Surg Pathol 1999;23:992.
20. Nakamura S, Koshikawa T, Yatabe Y, Suchi T. Lymphoblastic lymphoma expressing CD56 and TdT. Am J Surg Pathol 1998;22:135-137.
21. Petrella T, Dalac S, Maynadie M, et al. CD4+CD56+ cutaneous neoplasms: a distinct hematologic entity? Groupe Francais d'Etude des Lymphomes Cutanés (GFELC). Am J Surg Pathol 1999;23:137-146.
22. Leroux D, Mugneret F, Callanan M, et al. CD4(+) CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting six major targets: a study of 21 cases by the Groupe Francais de Cytogénétique Hématologique. Blood 2002;99:4154-4159.
23. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid denderitic cells. Blood 2001;97:3210-3217.
24. Chan JKC. Natural killer cell neoplasms. Anat Pathol 1998;3:77-145.
25. Yamada O, Ichikawa M, Okamoto T, et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001;113:153-160.
26. Uchiyama N, Kawai K, Takagi M, et al. A case of CD56-positive lymphoma. In: Takigawa M, editor. Lymphomas of the skin [Japanese]. Hamamatsu: Japanese Society for Cutaneous Lymphomas; 1996, vol 15. p 202-204.
27. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994;47:278-282.
28. Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia. Cancer 1995;75:2474-2483.
29. Koita H, Suzumiya J, Ohshima K, et al. Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. Am J Surg Pathol 1999;21:242-248.
30. Ichinohasama R, Endoh K, Ishizawa K, et al. Thymic lymphoblastic lymphoma of committed natural killer cell precursor origin. A case report. Cancer 1996;77:2592-2603.
31. Nakamura S, Katoh E, Koshikawa T, et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 1997;47: 38-53.
32. Savoia P, Fierro MT, Novelli M, et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 1997;137:966-971.
33. Dummer R, Potoczna N, Haffner AC, et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol 1996;132: 550-553.